MA52894A - 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci - Google Patents
19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ciInfo
- Publication number
- MA52894A MA52894A MA052894A MA52894A MA52894A MA 52894 A MA52894 A MA 52894A MA 052894 A MA052894 A MA 052894A MA 52894 A MA52894 A MA 52894A MA 52894 A MA52894 A MA 52894A
- Authority
- MA
- Morocco
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52894A true MA52894A (fr) | 2021-04-21 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052894A MA52894A (fr) | 2018-06-12 | 2019-06-12 | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210338692A1 (fr) |
| EP (1) | EP3806863A1 (fr) |
| JP (2) | JP2021527092A (fr) |
| KR (1) | KR20210021005A (fr) |
| CN (2) | CN112533611A (fr) |
| AU (1) | AU2019287491A1 (fr) |
| CA (1) | CA3103421A1 (fr) |
| IL (1) | IL279315A (fr) |
| MA (1) | MA52894A (fr) |
| MX (1) | MX2020013557A (fr) |
| SG (1) | SG11202012344RA (fr) |
| TW (1) | TW202005653A (fr) |
| WO (1) | WO2019241442A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2806877T1 (sl) | 2012-01-23 | 2020-01-31 | Sage Therapeutics, Inc. | Nevroaktivne steroidne formulacije, ki obsegajo kompleks alopregnanolona in sulfobutil etra beta-ciklodekstrina |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| SG11201901445TA (en) | 2016-08-23 | 2019-03-28 | Sage Therapeutics Inc | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP2023504517A (ja) * | 2019-12-05 | 2023-02-03 | セージ セラピューティクス， インコーポレイテッド | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| US20230414636A1 (en) | 2020-03-25 | 2023-12-28 | Sage Therapeutics, Inc. | Use of gabaa modulators for treatment of respiratory conditions |
| AR123018A1 (es) * | 2020-07-20 | 2022-10-26 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
| CA3213744A1 (fr) * | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | Steroide 19-nor c3,3-disubstitue c21-n-pyrazolyl pour le traitement d'un trouble depressif majeur |
| WO2022232494A1 (fr) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Stéroïde neuroactif destiné à être utilisé dans le traitement d'un trouble dépressif majeur et de la dépression post-partum chez une femme allaitante |
| JP2024515829A (ja) * | 2021-04-29 | 2024-04-10 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
| WO2023158668A1 (fr) * | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de troubles liés au snc |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512165B2 (en) * | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| HUE051488T2 (hu) * | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| JOP20170059B1 (ar) * | 2016-03-08 | 2021-08-17 | Sage Therapeutics Inc | ستيرويدات وتركيبات نشطة عصبيًا واستخداماتها |
| SG11201901445TA (en) * | 2016-08-23 | 2019-03-28 | Sage Therapeutics Inc | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (fr) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs méthodes d'utilisation |
-
2019
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/fr unknown
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko unknown
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/fr active Pending
- 2019-06-12 CA CA3103421A patent/CA3103421A1/fr active Pending
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020013557A (es) | 2021-05-27 |
| IL279315A (en) | 2021-01-31 |
| SG11202012344RA (en) | 2021-01-28 |
| CN117959309A (zh) | 2024-05-03 |
| TW202005653A (zh) | 2020-02-01 |
| CN112533611A (zh) | 2021-03-19 |
| US20210338692A1 (en) | 2021-11-04 |
| KR20210021005A (ko) | 2021-02-24 |
| US20220323462A1 (en) | 2022-10-13 |
| US20200113917A1 (en) | 2020-04-16 |
| CA3103421A1 (fr) | 2019-12-19 |
| AU2019287491A1 (en) | 2021-01-07 |
| JP2024028849A (ja) | 2024-03-05 |
| EP3806863A1 (fr) | 2021-04-21 |
| WO2019241442A1 (fr) | 2019-12-19 |
| JP2021527092A (ja) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52894A (fr) | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci | |
| MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
| MA45599A (fr) | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation | |
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| EP3878863A4 (fr) | Anticorps anti-claudin18.2 et son utilisation | |
| MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| SG10202111141WA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| EP3670656A4 (fr) | Procédé de quantification des odeurs, cellules utilisées dans ce procédé et procédé de production desdites cellules | |
| EP3495391A4 (fr) | Anticorps dirigé contre le ligand 1 de mort programmée (pd-l1) et son utilisation | |
| EP3876131A4 (fr) | Dispositif de conception de matériau, procédé de conception de matériau et programme de conception de matériau | |
| EP3765849A4 (fr) | Système de détermination, dispositif informatique, procédé de détermination et programme | |
| EP3824096A4 (fr) | Nouveaux anticorps et leurs procédés de préparation et d'utilisation | |
| SG10201907275UA (en) | Method of operating storage device, storage device performing the same and method of operating storage system using the same | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
| EP3848833A4 (fr) | Dispositif d'attribution de fonction d'analyse, procédé d'attribution de fonction d'analyse et programme d'attribution de fonction d'analyse | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| EP3844184A4 (fr) | Activation de cellules présentatrices d'antigènes et procédés d'utilisation de celles-ci | |
| IL278926A (en) | Antibodies specific to CD3 and their uses | |
| MA53167A (fr) | Récepteurs chimériques de steap1 et procédés d'utilisation associées | |
| EP3883691A4 (fr) | Puces microfluidiques à génération de gouttelettes et chargées sous vide et procédés associés | |
| MA50516A (fr) | Anticorps anti-apoc3 et leurs procédés d'utilisation |